Cyclosporin A in an adhesive base for treatment of recalcitrant oral lichen planus. An open trial.
Patients with symptomatic oral lichen planus often require therapy to reduce signs and symptoms of the condition. For this purpose, corticosteroids are frequently used. In this study the effect of another immunosuppressive drug, cyclosporin A was evaluated; it was applied as a topical drug four times daily and contained 0.025% cyclosporin A. The study group was composed of nine symptomatic patients in whom the diagnosis of oral lichen planus was confirmed by histopathologic examination including immunofluorescence. All patients had unsuccessfully undergone previous treatment with topical or systemic corticosteroids. The minimum follow-up period in the present study was at least 4 months. Four patients showed partial response to treatment with respect to signs and symptoms. None of the patients had a complete remission. Five patients showed no response or even complained of an increase of signs and symptoms. No adverse side effects of the drug were recorded during follow-up. Although the number of patients has been small, the results of this study indicate that topical application of cyclosporin A (0.025%) in the treatment of recalcitrant oral lichen planus does not offer a distinct advantage over the use of topical corticosteroids.
Voûte
A B
AB
Department of Oral and Maxillofacial Surgery and Oral Pathology, Free University Hospital/Academic Centre for Dentistry (ACTA), The Netherlands.
Schulten
E A
EA
Langendijk
P N
PN
Nieboer
C
C
van der Waal
I
I
D000287:Administration, Topical; D000328:Adult; D002908:Chronic Disease; D016572:Cyclosporine / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017676:Lichen Planus, Oral / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009824:Ointments; D010147:Pain Measurement
D009824:Ointments; D016572:Cyclosporine